Biofrontera Inc. (BFRI) Stock Price & Analysis
Biofrontera Inc. (BFRI) rose 0.00% to USD 1.09 as of July 25, 2026 at 08:14 UTC, according to Nexqual real-time market data.
BFRI last closed at USD 1.09; the session ranged USD 1.07–1.09 on volume of 165,175 shares. Market capitalization is $13.96M, with a 52-week range of USD 0.56–1.21 (NCM). Source: Nexqual, July 25, 2026 at 08:14 UTC.
Key Statistics (as of July 25, 2026 at 08:14 UTC)
| Price | USD 1.09 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.09 |
| Open | USD 1.08 |
| Day Range | USD 1.07 – 1.09 |
| 52-Week Range | USD 0.56 – 1.21 |
| Volume | 165,175 shares |
| Market Cap | $13.96M |
| Exchange | NCM |
Technical Analysis (BFRI)
Nexqual's technical model rates BFRI "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 08:14 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 55.35 (neutral) |
| vs SMA50 | Above (USD 0.98) |
| MACD | 0.03 (positive) |
Analyst Ratings (BFRI)
Wall Street analysts rate BFRI "None" based on 2 analysts, with a mean price target of USD 5.88 (range USD 2.75–9), per Nexqual as of July 25, 2026 at 08:14 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 5.88 |
| High Target | USD 9 |
| Low Target | USD 2.75 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (BFRI)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.04 |
| Revenue Estimate | $9.50M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.41 vs est -0.05 ▼ miss |
| 2025-12-31 | USD 0.5 vs est 0.1 ▲ beat |
| 2025-09-30 | USD -0.57 vs est -0.56 ▼ miss |
| 2025-06-30 | USD -0.57 vs est -0.39 ▼ miss |
Source: Nexqual, July 25, 2026 at 08:14 UTC.
Financials & Fundamentals (BFRI)
| Total Revenue | $43.20M |
|---|---|
| Revenue Growth (YoY) | +17.40% |
| Gross Margin | +77.29% |
| Operating Margin | -38.95% |
| Profit Margin | -25.66% |
| ROE | -339.04% |
| Debt / Equity | 127.25 |
| Current Ratio | 1.21 |
| Total Cash | $6.33M |
| Total Debt | $7.72M |
| Free Cash Flow | $1.48M |
Source: Nexqual, July 25, 2026 at 08:14 UTC.
Financial Health Score (BFRI)
Nexqual rates Biofrontera Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 08:14 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $6M cash vs $8M debt |
| Cash Flow | Mixed — FCF $1M, slim 3.5% margin |
| Efficiency | Critical — ROE -339%, ROA -32.4% |
Ownership (BFRI)
| Insider Ownership | +13.18% |
|---|---|
| Institutional Ownership | +22.42% |
| Shares Outstanding | 12.80M |
| Float | 9.08M |
| Short % of Float | +0.20% |
Source: Nexqual, July 25, 2026 at 08:14 UTC.
Leadership (BFRI)
Biofrontera Inc. is led by Hermann Luebbert (age 69), CEO, President & Chairman, per Nexqual as of July 25, 2026 at 08:14 UTC.
| CEO, President & Chairman | Hermann Luebbert (age 69) |
|---|---|
| Chief Financial Officer | Eugene Frederick Leffler (age 40) |
| Vice President of Scientific & Medical Affairs | Jon Lyons |
| Senior Vice President of Sales & Strategic Accounts | Samantha Widdicombe |
Major Backers & Investors (BFRI)
Notable institutional backers of Biofrontera Inc. include Rosalind Advisors, Inc., AIGH Capital Management LLC, Fidelity, according to Nexqual as of July 25, 2026 at 08:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Rosalind Advisors, Inc. | 9.09% |
| AIGH Capital Management LLC | 7.15% |
| Fidelity | 0.66% |
| Susquehanna International Group, LLP | 0.3% |
| Xtx Topco Ltd | 0.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.3% |
| Geode Capital | 0.85% |
Source: Nexqual, July 25, 2026 at 08:14 UTC.
From Biofrontera Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PTPI | Petros Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
| ISPC | iSpecimen Inc. | USD 1.97 | ▼ 12.44% |
| LGVN | Longeveron Inc. | USD 0.6 | ▼ 4.31% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.26 | ▼ 7.96% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.46 | ▼ 1.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 08:14 UTC. This page is informational and not investment advice.